| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 160 | 2024 | 5097 | 6.870 |
Why?
|
| Anti-HIV Agents | 78 | 2022 | 1324 | 6.550 |
Why?
|
| Anti-Retroviral Agents | 34 | 2019 | 551 | 3.570 |
Why?
|
| Antiretroviral Therapy, Highly Active | 45 | 2020 | 472 | 3.270 |
Why?
|
| Adult | 147 | 2024 | 5913 | 2.880 |
Why?
|
| Tuberculosis, Pulmonary | 24 | 2023 | 324 | 2.870 |
Why?
|
| Humans | 215 | 2024 | 14537 | 2.810 |
Why?
|
| South Africa | 143 | 2024 | 7596 | 2.470 |
Why?
|
| Male | 137 | 2022 | 6754 | 2.400 |
Why?
|
| Tuberculosis | 27 | 2023 | 543 | 2.390 |
Why?
|
| Female | 147 | 2022 | 9103 | 2.230 |
Why?
|
| CD4 Lymphocyte Count | 56 | 2019 | 656 | 2.200 |
Why?
|
| Adenine | 9 | 2014 | 91 | 2.100 |
Why?
|
| Antitubercular Agents | 20 | 2023 | 322 | 2.080 |
Why?
|
| Hepatitis C | 4 | 2024 | 37 | 1.860 |
Why?
|
| Viral Load | 44 | 2024 | 819 | 1.850 |
Why?
|
| Organophosphonates | 8 | 2014 | 45 | 1.760 |
Why?
|
| Treatment Outcome | 46 | 2022 | 889 | 1.760 |
Why?
|
| Stavudine | 13 | 2014 | 78 | 1.610 |
Why?
|
| Acquired Immunodeficiency Syndrome | 15 | 2016 | 187 | 1.550 |
Why?
|
| HIV-1 | 30 | 2020 | 1260 | 1.510 |
Why?
|
| Rifampin | 12 | 2023 | 197 | 1.490 |
Why?
|
| Middle Aged | 67 | 2022 | 3601 | 1.380 |
Why?
|
| Mycobacterium tuberculosis | 17 | 2021 | 329 | 1.330 |
Why?
|
| Ambulatory Care | 7 | 2017 | 54 | 1.240 |
Why?
|
| Young Adult | 49 | 2022 | 2498 | 1.160 |
Why?
|
| Primary Health Care | 13 | 2017 | 240 | 1.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2016 | 118 | 1.110 |
Why?
|
| International Cooperation | 5 | 2022 | 50 | 1.110 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2019 | 529 | 1.090 |
Why?
|
| Adolescent | 45 | 2022 | 2985 | 1.080 |
Why?
|
| Hepatitis C, Chronic | 3 | 2022 | 26 | 1.070 |
Why?
|
| Mass Vaccination | 3 | 2022 | 11 | 1.050 |
Why?
|
| Cohort Studies | 32 | 2019 | 967 | 1.030 |
Why?
|
| Sputum | 12 | 2019 | 135 | 1.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 12 | 2016 | 151 | 0.940 |
Why?
|
| HIV Seropositivity | 8 | 2016 | 265 | 0.930 |
Why?
|
| Drug Resistance, Bacterial | 6 | 2018 | 135 | 0.920 |
Why?
|
| Laboratories | 2 | 2024 | 47 | 0.910 |
Why?
|
| AIDS-Related Opportunistic Infections | 11 | 2018 | 195 | 0.880 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 13 | 2021 | 226 | 0.840 |
Why?
|
| Time Factors | 22 | 2018 | 507 | 0.800 |
Why?
|
| Health Resources | 6 | 2019 | 66 | 0.790 |
Why?
|
| Cost-Benefit Analysis | 12 | 2017 | 253 | 0.780 |
Why?
|
| Retrospective Studies | 18 | 2022 | 799 | 0.770 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 112 | 0.760 |
Why?
|
| Patient Compliance | 11 | 2020 | 120 | 0.740 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 11 | 0.740 |
Why?
|
| Drug Monitoring | 2 | 2014 | 55 | 0.730 |
Why?
|
| Body Mass Index | 6 | 2019 | 321 | 0.730 |
Why?
|
| Health Care Costs | 11 | 2021 | 115 | 0.700 |
Why?
|
| Tenofovir | 11 | 2020 | 171 | 0.700 |
Why?
|
| Prospective Studies | 27 | 2021 | 1160 | 0.690 |
Why?
|
| Sensitivity and Specificity | 17 | 2024 | 385 | 0.690 |
Why?
|
| Circumcision, Male | 1 | 2022 | 99 | 0.690 |
Why?
|
| Algorithms | 6 | 2020 | 106 | 0.690 |
Why?
|
| Coinfection | 11 | 2020 | 276 | 0.680 |
Why?
|
| HIV | 15 | 2023 | 380 | 0.680 |
Why?
|
| Point-of-Care Systems | 7 | 2020 | 91 | 0.660 |
Why?
|
| Lamivudine | 8 | 2020 | 89 | 0.640 |
Why?
|
| Lost to Follow-Up | 7 | 2017 | 62 | 0.630 |
Why?
|
| Biomedical Research | 2 | 2015 | 49 | 0.630 |
Why?
|
| Proportional Hazards Models | 17 | 2019 | 163 | 0.630 |
Why?
|
| Drug Therapy, Combination | 13 | 2023 | 279 | 0.610 |
Why?
|
| Fertilization | 5 | 2019 | 22 | 0.610 |
Why?
|
| RNA, Viral | 13 | 2024 | 303 | 0.600 |
Why?
|
| Bacteriological Techniques | 4 | 2014 | 54 | 0.590 |
Why?
|
| Risk Factors | 22 | 2021 | 1475 | 0.590 |
Why?
|
| Point-of-Care Testing | 7 | 2021 | 71 | 0.580 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 9 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2017 | 256 | 0.570 |
Why?
|
| Drug Resistance, Viral | 8 | 2016 | 278 | 0.570 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 56 | 0.560 |
Why?
|
| Quality of Life | 7 | 2022 | 177 | 0.550 |
Why?
|
| Drug Administration Schedule | 15 | 2021 | 156 | 0.540 |
Why?
|
| Patient Care | 2 | 2014 | 10 | 0.530 |
Why?
|
| Health Services Accessibility | 7 | 2022 | 280 | 0.510 |
Why?
|
| Benzoxazines | 6 | 2015 | 123 | 0.500 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2020 | 59 | 0.490 |
Why?
|
| Health Personnel | 7 | 2024 | 231 | 0.490 |
Why?
|
| Developing Countries | 8 | 2016 | 400 | 0.490 |
Why?
|
| Papillomavirus Infections | 3 | 2019 | 74 | 0.480 |
Why?
|
| Hepacivirus | 4 | 2024 | 37 | 0.470 |
Why?
|
| Nevirapine | 4 | 2014 | 146 | 0.460 |
Why?
|
| Prevalence | 19 | 2020 | 1192 | 0.450 |
Why?
|
| Tissue Banks | 1 | 2015 | 1 | 0.450 |
Why?
|
| Ownership | 1 | 2015 | 2 | 0.450 |
Why?
|
| Intellectual Property | 1 | 2015 | 3 | 0.440 |
Why?
|
| Delivery of Health Care | 3 | 2015 | 239 | 0.440 |
Why?
|
| Didanosine | 3 | 2010 | 11 | 0.440 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 284 | 0.430 |
Why?
|
| HIV Protease Inhibitors | 5 | 2016 | 92 | 0.420 |
Why?
|
| Aged | 19 | 2022 | 1740 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2018 | 132 | 0.420 |
Why?
|
| Specimen Handling | 1 | 2015 | 105 | 0.420 |
Why?
|
| Ethics Committees, Clinical | 1 | 2014 | 1 | 0.410 |
Why?
|
| Ethics Committees, Research | 1 | 2014 | 5 | 0.410 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 5 | 2016 | 33 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 260 | 0.400 |
Why?
|
| Treatment Failure | 11 | 2018 | 175 | 0.400 |
Why?
|
| Phosphorous Acids | 1 | 2013 | 14 | 0.400 |
Why?
|
| Medication Adherence | 6 | 2019 | 151 | 0.390 |
Why?
|
| Dietary Supplements | 1 | 2013 | 40 | 0.390 |
Why?
|
| Registries | 2 | 2012 | 91 | 0.390 |
Why?
|
| Candidiasis, Oral | 2 | 2012 | 8 | 0.370 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 370 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 8 | 2016 | 125 | 0.370 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2018 | 472 | 0.370 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2009 | 9 | 0.360 |
Why?
|
| Ritonavir | 7 | 2012 | 137 | 0.350 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 231 | 0.350 |
Why?
|
| Family Characteristics | 4 | 2016 | 135 | 0.350 |
Why?
|
| Malnutrition | 1 | 2012 | 56 | 0.350 |
Why?
|
| Biomarkers | 8 | 2020 | 327 | 0.340 |
Why?
|
| Incidence | 9 | 2019 | 685 | 0.340 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 31 | 0.330 |
Why?
|
| Vaccines | 2 | 2022 | 86 | 0.330 |
Why?
|
| Influenza B virus | 1 | 2011 | 42 | 0.330 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 54 | 0.320 |
Why?
|
| Papillomaviridae | 2 | 2019 | 34 | 0.320 |
Why?
|
| Pregnancy | 9 | 2019 | 1862 | 0.310 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 2009 | 3 | 0.310 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2019 | 106 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 125 | 0.300 |
Why?
|
| Data Collection | 1 | 2010 | 86 | 0.300 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2016 | 35 | 0.290 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 144 | 0.290 |
Why?
|
| Hospitalization | 4 | 2023 | 418 | 0.290 |
Why?
|
| Hospitals | 3 | 2023 | 103 | 0.280 |
Why?
|
| Urban Population | 7 | 2016 | 257 | 0.280 |
Why?
|
| Sexual Partners | 5 | 2017 | 215 | 0.280 |
Why?
|
| Reproductive Health | 3 | 2019 | 51 | 0.270 |
Why?
|
| Child | 8 | 2022 | 2242 | 0.270 |
Why?
|
| Pyrimidinones | 4 | 2010 | 24 | 0.260 |
Why?
|
| Office Visits | 2 | 2017 | 6 | 0.260 |
Why?
|
| Antiviral Agents | 3 | 2022 | 111 | 0.260 |
Why?
|
| Zambia | 4 | 2022 | 115 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2011 | 374 | 0.250 |
Why?
|
| Myanmar | 2 | 2024 | 2 | 0.250 |
Why?
|
| Liver | 3 | 2008 | 74 | 0.250 |
Why?
|
| Public Sector | 7 | 2018 | 82 | 0.250 |
Why?
|
| Pyridines | 2 | 2003 | 11 | 0.240 |
Why?
|
| Oligopeptides | 2 | 2003 | 16 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2022 | 150 | 0.240 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 1422 | 0.240 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2017 | 7 | 0.240 |
Why?
|
| Malawi | 4 | 2021 | 87 | 0.230 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2024 | 90 | 0.230 |
Why?
|
| Lipid Metabolism | 4 | 2013 | 44 | 0.230 |
Why?
|
| Program Evaluation | 4 | 2014 | 89 | 0.220 |
Why?
|
| Prognosis | 6 | 2022 | 199 | 0.220 |
Why?
|
| Drug Substitution | 2 | 2016 | 33 | 0.220 |
Why?
|
| Alkynes | 6 | 2015 | 117 | 0.220 |
Why?
|
| Cyclopropanes | 6 | 2015 | 123 | 0.220 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2021 | 47 | 0.220 |
Why?
|
| Hospitals, Urban | 2 | 2016 | 23 | 0.210 |
Why?
|
| Patient Selection | 3 | 2014 | 40 | 0.210 |
Why?
|
| Disease Transmission, Infectious | 3 | 2013 | 39 | 0.210 |
Why?
|
| Logistic Models | 3 | 2016 | 254 | 0.200 |
Why?
|
| Thrombosis | 1 | 2024 | 47 | 0.200 |
Why?
|
| Genotype | 8 | 2022 | 442 | 0.200 |
Why?
|
| Laboratory Infection | 1 | 2023 | 5 | 0.190 |
Why?
|
| Metabolic Diseases | 1 | 2003 | 30 | 0.190 |
Why?
|
| Cost of Illness | 4 | 2021 | 167 | 0.190 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 40 | 0.190 |
Why?
|
| Voluntary Programs | 1 | 2022 | 5 | 0.190 |
Why?
|
| Demography | 3 | 2013 | 105 | 0.190 |
Why?
|
| Ukraine | 1 | 2022 | 2 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 188 | 0.180 |
Why?
|
| Pain | 1 | 2022 | 41 | 0.180 |
Why?
|
| Body Composition | 2 | 2013 | 153 | 0.180 |
Why?
|
| Mass Screening | 4 | 2020 | 245 | 0.180 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 237 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2022 | 18 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2016 | 225 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 11 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 30 | 0.180 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 101 | 0.180 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 13 | 0.180 |
Why?
|
| Triazoles | 2 | 2015 | 20 | 0.180 |
Why?
|
| Pandemics | 2 | 2022 | 296 | 0.170 |
Why?
|
| Employment | 2 | 2014 | 27 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2021 | 10 | 0.170 |
Why?
|
| Immunoassay | 1 | 2021 | 28 | 0.170 |
Why?
|
| Health Services | 3 | 2010 | 51 | 0.170 |
Why?
|
| Palliative Care | 1 | 2001 | 52 | 0.170 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 39 | 0.170 |
Why?
|
| Women's Health | 2 | 2012 | 41 | 0.170 |
Why?
|
| Hydroxyurea | 1 | 2001 | 2 | 0.170 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 56 | 0.170 |
Why?
|
| Public Health Administration | 1 | 2020 | 14 | 0.170 |
Why?
|
| Clinical Protocols | 2 | 2017 | 26 | 0.160 |
Why?
|
| Health Equity | 1 | 2020 | 12 | 0.160 |
Why?
|
| Lopinavir | 6 | 2012 | 137 | 0.160 |
Why?
|
| Time-to-Treatment | 3 | 2015 | 42 | 0.160 |
Why?
|
| Immunologic Tests | 1 | 2020 | 7 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 127 | 0.160 |
Why?
|
| Glycomics | 1 | 2020 | 2 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.160 |
Why?
|
| Patient Dropouts | 2 | 2010 | 18 | 0.160 |
Why?
|
| Comorbidity | 3 | 2017 | 188 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.160 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2013 | 12 | 0.160 |
Why?
|
| HIV-2 | 1 | 2020 | 15 | 0.160 |
Why?
|
| Health Expenditures | 2 | 2013 | 39 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 468 | 0.160 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 44 | 0.150 |
Why?
|
| Nelfinavir | 3 | 2004 | 6 | 0.150 |
Why?
|
| Tanzania | 4 | 2022 | 88 | 0.150 |
Why?
|
| DNA, Bacterial | 3 | 2016 | 53 | 0.150 |
Why?
|
| Counseling | 3 | 2015 | 143 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2B6 | 3 | 2015 | 16 | 0.150 |
Why?
|
| Child, Orphaned | 1 | 2019 | 16 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2016 | 17 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2019 | 22 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 14 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Gene Expression | 1 | 2019 | 43 | 0.150 |
Why?
|
| Cluster Analysis | 4 | 2021 | 65 | 0.140 |
Why?
|
| AIDS Dementia Complex | 2 | 2012 | 29 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.140 |
Why?
|
| Glucose | 3 | 2013 | 45 | 0.140 |
Why?
|
| Hemoglobins | 3 | 2016 | 40 | 0.140 |
Why?
|
| Social Stigma | 1 | 2019 | 80 | 0.140 |
Why?
|
| Research Design | 2 | 2017 | 124 | 0.140 |
Why?
|
| Zidovudine | 3 | 2011 | 59 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2019 | 149 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 64 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 22 | 0.140 |
Why?
|
| Dideoxynucleosides | 1 | 2018 | 29 | 0.140 |
Why?
|
| Referral and Consultation | 3 | 2014 | 57 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 253 | 0.130 |
Why?
|
| Drug Costs | 1 | 2017 | 18 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2017 | 15 | 0.130 |
Why?
|
| Weight Gain | 2 | 2019 | 77 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 115 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2013 | 272 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2017 | 101 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 11 | 0.130 |
Why?
|
| Hepatitis B | 2 | 2008 | 125 | 0.130 |
Why?
|
| Public Health | 2 | 2018 | 124 | 0.130 |
Why?
|
| Adamantane | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ethylenediamines | 1 | 2016 | 1 | 0.130 |
Why?
|
| Safe Sex | 1 | 2017 | 68 | 0.120 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 20 | 0.120 |
Why?
|
| Africa South of the Sahara | 4 | 2019 | 353 | 0.120 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 411 | 0.120 |
Why?
|
| DNA, Mitochondrial | 2 | 2013 | 31 | 0.120 |
Why?
|
| Hepatitis B virus | 2 | 2020 | 157 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 262 | 0.120 |
Why?
|
| Obesity | 1 | 2019 | 367 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 45 | 0.120 |
Why?
|
| Lymphocyte Activation | 3 | 2015 | 40 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2013 | 64 | 0.120 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2017 | 196 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2016 | 10 | 0.120 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 5 | 0.120 |
Why?
|
| Inpatients | 1 | 2016 | 30 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2015 | 4 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2016 | 39 | 0.120 |
Why?
|
| Inflammation | 2 | 2013 | 104 | 0.120 |
Why?
|
| Cyclohexanes | 1 | 2015 | 5 | 0.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2016 | 19 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 9 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2019 | 1748 | 0.120 |
Why?
|
| Monocytes | 1 | 2015 | 27 | 0.120 |
Why?
|
| Isoniazid | 4 | 2023 | 110 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 41 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2013 | 48 | 0.110 |
Why?
|
| Patient Preference | 1 | 2015 | 30 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 37 | 0.110 |
Why?
|
| Drug Design | 1 | 2015 | 29 | 0.110 |
Why?
|
| Cognition | 1 | 2016 | 75 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 77 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2013 | 133 | 0.110 |
Why?
|
| Informed Consent | 1 | 2015 | 8 | 0.110 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2015 | 10 | 0.110 |
Why?
|
| Alanine Transaminase | 3 | 2016 | 23 | 0.110 |
Why?
|
| DNA, Viral | 3 | 2013 | 165 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 45 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 106 | 0.110 |
Why?
|
| World Health Organization | 4 | 2021 | 137 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2014 | 4 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 34 | 0.100 |
Why?
|
| Resource Allocation | 2 | 2012 | 16 | 0.100 |
Why?
|
| Transcriptome | 1 | 2014 | 14 | 0.100 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2014 | 27 | 0.100 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 2 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 217 | 0.100 |
Why?
|
| Hypertension | 1 | 2018 | 419 | 0.100 |
Why?
|
| Africa | 5 | 2016 | 376 | 0.100 |
Why?
|
| Mycobacterium | 1 | 2014 | 16 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2014 | 57 | 0.100 |
Why?
|
| Contact Tracing | 1 | 2014 | 48 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 28 | 0.100 |
Why?
|
| Pericarditis, Tuberculous | 1 | 2013 | 8 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2013 | 8 | 0.100 |
Why?
|
| Energy Intake | 1 | 2013 | 24 | 0.100 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2013 | 8 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2013 | 31 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 51 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 46 | 0.100 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2013 | 8 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 59 | 0.100 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 45 | 0.100 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2013 | 6 | 0.100 |
Why?
|
| Anthropometry | 1 | 2013 | 102 | 0.100 |
Why?
|
| Postnatal Care | 1 | 2013 | 13 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 12 | 0.100 |
Why?
|
| Infant | 5 | 2019 | 2244 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2013 | 179 | 0.100 |
Why?
|
| Global Health | 2 | 2012 | 193 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 33 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 106 | 0.090 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 6 | 0.090 |
Why?
|
| Autoantigens | 1 | 2012 | 10 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2012 | 21 | 0.090 |
Why?
|
| Mutation | 4 | 2016 | 306 | 0.090 |
Why?
|
| Adipocytes | 1 | 2012 | 23 | 0.090 |
Why?
|
| Diagnostic Equipment | 1 | 2012 | 3 | 0.090 |
Why?
|
| Government Programs | 1 | 2012 | 30 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 42 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 435 | 0.090 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 41 | 0.090 |
Why?
|
| Models, Biological | 2 | 2012 | 77 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.090 |
Why?
|
| Age Factors | 4 | 2016 | 370 | 0.090 |
Why?
|
| Interviews as Topic | 3 | 2019 | 203 | 0.090 |
Why?
|
| Health Status | 2 | 2009 | 111 | 0.090 |
Why?
|
| Disease Progression | 4 | 2014 | 154 | 0.090 |
Why?
|
| Nurse Administrators | 1 | 2011 | 9 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 7 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2011 | 1 | 0.090 |
Why?
|
| Prenatal Care | 1 | 2013 | 147 | 0.090 |
Why?
|
| Nursing | 1 | 2011 | 5 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 52 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 293 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 41 | 0.090 |
Why?
|
| Sustained Virologic Response | 2 | 2022 | 22 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 23 | 0.090 |
Why?
|
| Kidney | 1 | 2011 | 46 | 0.090 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.080 |
Why?
|
| Oropharynx | 1 | 2011 | 17 | 0.080 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 23 | 0.080 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 23 | 0.080 |
Why?
|
| Placebos | 1 | 2011 | 44 | 0.080 |
Why?
|
| National Health Programs | 3 | 2017 | 78 | 0.080 |
Why?
|
| United States | 4 | 2016 | 132 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 26 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2010 | 10 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 10 | 0.080 |
Why?
|
| Adiposity | 1 | 2011 | 96 | 0.080 |
Why?
|
| Physicians | 1 | 2010 | 31 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 303 | 0.080 |
Why?
|
| Pyridazines | 1 | 2009 | 6 | 0.080 |
Why?
|
| South America | 3 | 2016 | 27 | 0.080 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 7 | 0.080 |
Why?
|
| Medically Underserved Area | 2 | 2016 | 13 | 0.080 |
Why?
|
| Prednisone | 1 | 2009 | 17 | 0.080 |
Why?
|
| Research | 1 | 2010 | 65 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 39 | 0.080 |
Why?
|
| Health Priorities | 1 | 2010 | 62 | 0.070 |
Why?
|
| Nurse-Patient Relations | 1 | 2009 | 2 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 563 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 25 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 48 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2019 | 21 | 0.070 |
Why?
|
| Papanicolaou Test | 1 | 2009 | 29 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2009 | 34 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 244 | 0.070 |
Why?
|
| Health Care Rationing | 2 | 2005 | 16 | 0.070 |
Why?
|
| Patient Care Management | 1 | 2008 | 9 | 0.070 |
Why?
|
| Viremia | 2 | 2022 | 66 | 0.070 |
Why?
|
| Outpatients | 1 | 2008 | 38 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2010 | 7 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2009 | 120 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 41 | 0.070 |
Why?
|
| Hospitals, Public | 1 | 2008 | 45 | 0.070 |
Why?
|
| CD8 Antigens | 1 | 2008 | 3 | 0.070 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Comprehensive Health Care | 1 | 2008 | 5 | 0.070 |
Why?
|
| Private Sector | 1 | 2008 | 45 | 0.070 |
Why?
|
| Survival Rate | 2 | 2014 | 96 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 73 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2021 | 26 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 43 | 0.070 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 16 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2006 | 4 | 0.060 |
Why?
|
| Atazanavir Sulfate | 2 | 2003 | 10 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2006 | 25 | 0.060 |
Why?
|
| Carbamates | 1 | 2006 | 12 | 0.060 |
Why?
|
| Organophosphates | 1 | 2006 | 9 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 10 | 0.060 |
Why?
|
| Fluconazole | 1 | 2006 | 17 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 181 | 0.060 |
Why?
|
| Candidiasis | 1 | 2006 | 15 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2006 | 40 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 55 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2019 | 321 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 60 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 133 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2004 | 11 | 0.050 |
Why?
|
| Length of Stay | 2 | 2016 | 43 | 0.050 |
Why?
|
| Educational Status | 2 | 2016 | 68 | 0.050 |
Why?
|
| Health Policy | 1 | 2005 | 140 | 0.050 |
Why?
|
| Creatinine | 2 | 2016 | 53 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2003 | 12 | 0.050 |
Why?
|
| Asia | 2 | 2016 | 72 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2016 | 65 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2003 | 3 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2003 | 3 | 0.050 |
Why?
|
| Virus Replication | 2 | 2020 | 88 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2022 | 5 | 0.050 |
Why?
|
| Lipids | 1 | 2003 | 81 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 227 | 0.050 |
Why?
|
| Capacity Building | 1 | 2022 | 32 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 22 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 57 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2022 | 14 | 0.050 |
Why?
|
| Africa, Southern | 2 | 2014 | 91 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 24 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 67 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 5 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2001 | 34 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 31 | 0.040 |
Why?
|
| MEDLINE | 1 | 2001 | 2 | 0.040 |
Why?
|
| Gambia | 1 | 2021 | 13 | 0.040 |
Why?
|
| Lesotho | 1 | 2020 | 6 | 0.040 |
Why?
|
| Mozambique | 1 | 2021 | 55 | 0.040 |
Why?
|
| Liver Diseases | 2 | 2014 | 18 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2020 | 8 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.040 |
Why?
|
| Health Facilities | 1 | 2020 | 40 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2020 | 12 | 0.040 |
Why?
|
| Oxidoreductases, N-Demethylating | 2 | 2013 | 6 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 8 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 16 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 109 | 0.040 |
Why?
|
| Markov Chains | 2 | 2011 | 22 | 0.040 |
Why?
|
| Motor Skills | 1 | 2019 | 6 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 16 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 36 | 0.040 |
Why?
|
| Spirometry | 1 | 2019 | 12 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 10 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 29 | 0.040 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2019 | 36 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 41 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 66 | 0.030 |
Why?
|
| Rural Population | 2 | 2015 | 654 | 0.030 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2017 | 4 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2014 | 1479 | 0.030 |
Why?
|
| Medical Audit | 1 | 2017 | 26 | 0.030 |
Why?
|
| Gene Products, pol | 1 | 2016 | 5 | 0.030 |
Why?
|
| Ethambutol | 1 | 2016 | 9 | 0.030 |
Why?
|
| Pyrazinamide | 1 | 2016 | 14 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2016 | 49 | 0.030 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 29 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 82 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 38 | 0.030 |
Why?
|
| Urban Health | 1 | 2016 | 78 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 89 | 0.030 |
Why?
|
| Rural Health | 1 | 2017 | 118 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 107 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 104 | 0.030 |
Why?
|
| Operations Research | 1 | 2016 | 3 | 0.030 |
Why?
|
| Verbal Learning | 1 | 2016 | 3 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2016 | 6 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 47 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 18 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 64 | 0.030 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2015 | 5 | 0.030 |
Why?
|
| Sierra Leone | 1 | 2015 | 11 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2016 | 34 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 480 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2015 | 11 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 15 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2016 | 49 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 93 | 0.030 |
Why?
|
| Intention | 1 | 2015 | 23 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 10 | 0.030 |
Why?
|
| Microscopy | 1 | 2015 | 21 | 0.030 |
Why?
|
| Peru | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 31 | 0.030 |
Why?
|
| Appendix | 1 | 1994 | 3 | 0.030 |
Why?
|
| Echinococcosis | 1 | 1994 | 6 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 1994 | 7 | 0.030 |
Why?
|
| Uganda | 1 | 2015 | 197 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 196 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2014 | 5 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gross Domestic Product | 1 | 2013 | 2 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 27 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 29 | 0.030 |
Why?
|
| Pericardiocentesis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 6 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2013 | 26 | 0.030 |
Why?
|
| India | 1 | 2013 | 62 | 0.030 |
Why?
|
| Phylogeny | 1 | 2013 | 231 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2013 | 17 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 80 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2012 | 27 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 171 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2012 | 10 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 111 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2012 | 17 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2012 | 5 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 3 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 158 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2013 | 79 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2012 | 24 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 11 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 147 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 42 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 139 | 0.020 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2011 | 5 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Spouses | 1 | 2011 | 6 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 85 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 37 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 107 | 0.020 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 4 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 16 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 119 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2010 | 13 | 0.020 |
Why?
|
| Financial Support | 1 | 2010 | 10 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2010 | 30 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 10 | 0.020 |
Why?
|
| Nitriles | 1 | 2009 | 27 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2009 | 32 | 0.020 |
Why?
|
| Weaning | 1 | 2009 | 4 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2009 | 26 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 87 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2008 | 14 | 0.020 |
Why?
|
| Fluorescence | 1 | 2008 | 9 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 111 | 0.020 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2007 | 1 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 11 | 0.020 |
Why?
|
| Models, Economic | 1 | 2007 | 15 | 0.020 |
Why?
|
| Transportation | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hospitals, County | 1 | 2007 | 2 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2006 | 11 | 0.020 |
Why?
|
| Time | 1 | 2006 | 3 | 0.020 |
Why?
|
| Furans | 1 | 2006 | 4 | 0.020 |
Why?
|
| Pharyngeal Diseases | 1 | 2006 | 1 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 27 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2006 | 122 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 99 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 15 | 0.010 |
Why?
|
| Candida | 1 | 2006 | 24 | 0.010 |
Why?
|
| Social Conditions | 1 | 2005 | 10 | 0.010 |
Why?
|
| Policy Making | 1 | 2005 | 32 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 198 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2005 | 6 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 11 | 0.010 |
Why?
|
| Culture | 1 | 2005 | 23 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 11 | 0.010 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2004 | 16 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2004 | 43 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 42 | 0.010 |
Why?
|
| Acidosis, Lactic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Triglycerides | 1 | 2003 | 47 | 0.010 |
Why?
|
| Emtricitabine | 1 | 2003 | 78 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 6 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 48 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 150 | 0.010 |
Why?
|
| Appendicitis | 1 | 1994 | 2 | 0.010 |
Why?
|
| Cecal Diseases | 1 | 1994 | 3 | 0.010 |
Why?
|
| Echinococcus | 1 | 1994 | 5 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 63 | 0.010 |
Why?
|
| Animals | 1 | 1994 | 1081 | 0.010 |
Why?
|